Core-Shell Ocular Microparticles for Six-Month Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD), such as monthly intravitreal injections of anti-VEGF agents, suffer from side effects like infection, elevated intraocular pressure, and rhegmatogenous retinal detachment, and existing microparticles release therapeutic agents too rapidly due to biodegradation within three months.
Innovation Solution
Development of drug delivery compositions comprising a core component with a positively charged first polymer and a biodegradable shell layer, allowing for extended release of therapeutic agents like anti-VEGF over six months, minimizing side effects and improving patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If microparticles or nanoparticles are used for drug delivery, then injection feasibility is improved, but drug release duration is insufficient (rapid release within three months)
Solution Approach 1:
The patent employs a composite particle structure consisting of a biodegradable polymer matrix combined with a non-biodegradable polymer shell. This composite approach allows the inner matrix to provide sustained drug release over extended periods (six months or longer) while the outer shell maintains particle integrity and enables intravitreal injection through 30-gauge needles, thus resolving the contradiction between injection feasibility and prolonged drug release duration.
2Reliability
If frequent intravitreal injections are administered, then treatment efficacy is maintained, but side effects increase (infection, elevated intraocular pressure, retinal detachment)
Solution Approach 1:
The patent implements continuous drug release from the microparticle formulation over an extended period of six months or longer. This continuous action maintains therapeutic efficacy throughout the treatment period, eliminating the need for frequent monthly injections and thereby reducing cumulative side effects such as infection risk, elevated intraocular pressure, and retinal detachment associated with repeated procedures.
3Duration of action of moving object
If implant devices are used for long-term drug delivery, then drug release duration is extended, but surgical complexity and off-target delivery increase
Solution Approach 1:
The patent utilizes disposable microparticle formulations that can be administered via simple intravitreal injection without requiring surgical implantation or subsequent removal procedures. These microparticles are designed to biodegrade naturally after completing their extended drug release function (six months or longer), eliminating the need for complex surgical interventions while maintaining prolonged therapeutic action.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions provide sustained release of therapeutic agents, reducing the frequency of injections and minimizing side effects, thereby enhancing treatment efficacy and patient compliance for AMD and other ocular diseases.
Implementation Method 1
a shell layer comprising a second polymer that is biodegradable under physiological conditions
Implementation Method 2
a core component comprising a therapeutic agent and a first polymer having a net positive charge under physiological conditions
Data Source
AI summary
In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.